STOCK TITAN

Vertex (NASDAQ: VRTX) shareholder files to sell 1,500 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vertex Pharmaceuticals shareholder Ourania Tatsis filed a Form 144 notice to sell 1,500 shares of Vertex common stock, with an aggregate market value of $749,992.02, through Fidelity Brokerage Services on NASDAQ around February 13, 2026.

The filing indicates 253,718,831 Vertex common shares outstanding. The 1,500 shares to be sold trace to restricted stock that vested as compensation in February 2021, in lots of 1,448 and 52 shares acquired from the issuer.

Over the past three months, Tatsis has sold additional Vertex common shares, including 4,500 shares on December 3, 2025 for gross proceeds of $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for Vertex (VRTX) by Ourania Tatsis disclose?

The Form 144 discloses that shareholder Ourania Tatsis plans to sell 1,500 shares of Vertex common stock. The shares have an aggregate market value of $749,992.02 and are expected to be sold on the NASDAQ through Fidelity Brokerage Services.

How many Vertex (VRTX) shares is the filer planning to sell under this Form 144?

The filer plans to sell 1,500 shares of Vertex common stock. The table lists an aggregate market value of $749,992.02 for this block, with the transaction expected to occur around February 13, 2026 on the NASDAQ exchange.

What prior Vertex (VRTX) stock sales has Ourania Tatsis reported in the last three months?

The filing shows three prior sales: 4,500 shares on December 3, 2025 for $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38 in gross proceeds.

How did Ourania Tatsis acquire the Vertex (VRTX) shares being sold under Form 144?

The shares were acquired through restricted stock vesting from the issuer as compensation. The filing lists vesting on February 10, 2021 for 1,448 shares and on February 17, 2021 for 52 shares, both categorized as compensation.

What does the Form 144 say about Vertex (VRTX) shares outstanding?

The Form 144 lists 253,718,831 shares of Vertex common stock as outstanding. This figure provides context for the size of the planned 1,500-share sale relative to the company’s total common equity base at the time of the filing.

Which broker and exchange are involved in the planned Vertex (VRTX) share sale?

The notice indicates the planned sale will be executed through Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island. The NASDAQ exchange is listed as the marketplace where the 1,500 Vertex common shares are expected to be sold.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

124.70B
253.12M
0.14%
98.18%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON